Document:

Form of Existing Stockholder's Letter Agreement

 EXHIBIT 10.12 
 FORM OF EXISTING STOCKHOLDER’S LETTER 
                  , 2007 
 Golden Pond Healthcare,
Inc. 
   18 Arrowhead Way 
   Darien, CT
06820 
 Deutsche Bank Securities Inc. 
   60 Wall
Street, 4th Floor 
   New York, New York 10005 
 Lazard Capital Markets LLC 
   30 Rockefeller Plaza 
   New York, New York 10020 
 Re: Initial Public Offering 
 Ladies and Gentlemen: 
 The undersigned1 [director] [senior advisor] [and] holder of common stock, par value $0.001 per share (“Common
Stock”) [and warrants (“Warrants”) to purchase shares of Common Stock]2, of Golden Pond Healthcare, Inc. (the
“Company”), in consideration of Deutsche Bank Securities Inc. and Lazard Capital Markets LLC (together, the “Underwriters”) agreeing to act as lead underwriters in connection with the initial public offering of the
securities of the Company (“IPO”), hereby agrees as follows: 
 1. Agreements of Stockholders

 (a) The undersigned hereby waives any right to receive distributions (other than with respect to Common Stock or any shares of Common Stock
underlying units the undersigned may purchase in connection with the IPO or in the after market) upon the liquidation of the Trust Fund (as defined in the Certificate of Incorporation of the Company (as amended, the “Certificate”;
capitalized terms used herein but not defined herein have the meaning set forth in the Certificate)), or as part of any plan of dissolution and distribution required in the event the Company does not consummate a Business Combination by the
Termination Date. 

	 1
	 To be signed by each existing stockholder (e.g., Pecksland, directors, special
advisors and other transferees, if any). 

	 2
	 Pecksland only. 

 (b) The undersigned hereby waives any right set forth in the Certificate to demand conversion of the
undersigned’s shares of Common Stock into cash (other than with respect to Common Stock or any shares of Common Stock underlying units the undersigned may purchase in connection with the IPO or in the after market) in the event a Business
Combination is approved by the Company’s stockholders. 
 (c) In connection with the stockholder vote required to approve a Business
Combination, the undersigned shall vote any shares of Common Stock purchased by the undersigned prior to the Company’s initial public offering in accordance with the majority of the shares of Common Stock voted by the Company’s public
stockholders. In connection with the stockholder vote for the Company’s plan of dissolution and distribution, if any, required as a result of the Company’s failure to consummate a Business Combination by the Termination Date, the
undersigned shall vote any shares of Common Stock purchased by the undersigned prior to the Company’s initial public offering in favor of such dissolution and distribution. 
 (d) The undersigned and any affiliate of the undersigned will not be entitled to receive from the Company, and will not accept from the Company, any
compensation (including finder’s or consulting fees) for services rendered to the Company prior to or in connection with the consummation of a Business Combination (except as described in the registration statement filed with and declared
effective by the Securities and Exchange Commission in connection with the IPO (the “Registration Statement”). 
 (e) The undersigned will escrow the shares of Common Stock [and the Warrants]3 owned by the undersigned immediately prior to the IPO pursuant to a stock escrow agreement until the earliest of (i) [with respect to the Common
Stock]3 one year from the completion of a Business Combination [and with respect to the Warrants ninety days from the completion of a Business
Combination]3, (ii) the Company’s liquidation and (iii) the consummation of a business combination which results in all of the
Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property subsequent to the Company’s consummating a Business Combination. 
 (f) The undersigned further agrees that he shall not hypothecate, donate, encumber or otherwise dispose of any interest in the membership interests of
Pecksland Partners, LLC until the earliest of (i) one year from the completion of a Business
 Combination, (ii) the Company’s liquidation and (iii) the consummation of a business combination which results in all of the
Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property subsequent to the Company’s consummating a Business Combination. 
 2. Agreements of Directors and Officers 
 (a) In the event that the Company does not consummate a Business Combination by the Termination Date, in the event the undersigned is a director of the Company, the undersigned, in his capacity as a Director of the Company,
(i) acknowledges the requirement set forth in the Certificate that the Board of Directors of the Company shall adopt, within 15 days after the Termination Date, a resolution finding the dissolution of the Company advisable and provide notices
to the Company’s stockholders as required by § 275(a) of the Delaware General Corporate Law as soon as reasonably practicable thereafter and (ii) will take all reasonable actions within the undersigned’s power to effect such
dissolution of the Company under the circumstances contemplated by the Certificate provided that at the time of such liquidation and dissolution the undersigned is a director. 

	 3
	 Pecksland only. 

 (b) In order to minimize potential conflicts of interest which may arise from multiple affiliations, in
the event the undersigned is an officer of the Company, the undersigned, in his capacity as an officer of the Company, agrees to present to the Company for its consideration, prior to presentation to any other person or entity, any suitable
opportunity to acquire an operating business, until the earlier of the consummation by the Company of a Business Combination, the liquidation of the Company or until such time as the undersigned is not an officer of the Company, subject to any
pre-existing fiduciary and contractual obligations the undersigned might have. 
 (c) The undersigned’s biographical information set
forth in the Registration Statement is true and accurate in all respects, does not omit any material information with respect to the undersigned’s background and contains all of the information required to be disclosed pursuant to Item 401
of Regulation S-K, promulgated under the Securities Act of 1933. The undersigned’s Director’s and Officer’s Questionnaire furnished to the Company in connection with the Registration Statement is true and accurate in all respects. The
undersigned represents and warrants that, except as disclosed in the undersigned’s Director’s and Officer’s Questionnaire: 
 i. the undersigned is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of
securities in any jurisdiction; 
 ii. the undersigned has never been convicted of or pleaded guilty to any crime
(i) involving any fraud or (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities, and is not currently a defendant in any such criminal proceeding; and

 iii. the undersigned has never been suspended or expelled from membership in any securities or commodities exchange or
association or had a securities or commodities license or registration denied, suspended or revoked.
 (d) The undersigned has full right and power, without violating any agreement by which he is bound, to enter into this letter agreement [and to serve as a member of the board of directors of the Company].4 
 3. Miscellaneous 
 (a) The undersigned has full right and power, without violating any agreement by which the undersigned is bound, to enter into this letter agreement.

	 4
	 Directors only. 

 (b) This letter agreement shall be governed by and construed and enforced in accordance with the laws of
the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The undersigned hereby (i) agrees that any action, proceeding or claim against him
arising out of or relating in any way to this letter agreement (a “ Proceeding “) shall be brought and enforced in the courts of the State of New York of the United States of America for the Southern District of New York, and
irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive, and (ii) waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. If for any reason such agent is unable to act as
such, the undersigned will promptly notify the Company and the Underwriters and appoint a substitute agent acceptable to the Underwriters within 30 days and nothing in this letter will affect the right of either party to serve process in any other
manner permitted by law. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned has executed this agreement as of the date first written above.

  

			
		
	By:	 	  

		 	 [Name]AMENDMENT NO. 1 TO LOAN & SECURITY AGREEMENT WITH HERCULES TECHNOLOGY

 Exhibit 10.21 
 AMENDMENT NO. 1 
 TO 
 LOAN AND SECURITY AGREEMENT 
 THIS AMENDMENT
NO. 1 TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 13th day of September, 2007, by and among
ELIXIR PHARMACEUTICALS, INC. (“Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a
Maryland corporation and HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership (collectively, the “Lender”). Capitalized terms used herein without definition shall have the same
meanings given them in the Loan Agreement (as defined below). 
 RECITALS 
 A. Borrower and Lender have entered into that certain Loan and Security Agreement dated as of November 21, 2006 (as may be amended, restated,
or otherwise modified, the “Loan Agreement”), pursuant to which the Lender has agreed to extend and make available to Borrower certain advances of money. 
 B. Borrower and Lender have agreed to amend the Loan Agreement upon the terms and conditions more fully set forth herein. 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing Recitals and intending to be legally bound, the parties hereto agree as follows: 
 1.
AMENDMENTS. 
 SECTION 2.1. The following is appended to
Section 2.1: 
 Notwithstanding any foregoing terms to the contrary, the date by which the Milestone Event is required to occur, and by
which Borrower may request a Tranche B Advance, is extended from June 30, 2007 to September 19, 2007. Any such Tranche B Advance remains subject to the other terms and conditions of this Agreement. 
 2. AMENDMENT CHARGE 
 Borrower agrees to pay a $12,500 amendment charge to Lender for entering into this Amendment and Borrower’s ability to draw under Tranche B is
contingent upon payment of such charge. 
 3. BORROWER’S REPRESENTATIONS
AND WARRANTIES. Borrower represents and warrants that: 
 (a)
immediately upon giving effect to this Amendment (i) the representations and warranties contained in the Loan Documents and the updates to the Disclosure Schedules attached hereto as Annex A are true, accurate and complete in all
material 

 
respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct
as of such date), and (ii) no Event of Default has occurred and is continuing; 
 (b) Borrower has the corporate
power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 
 (c) the certificate of incorporation, bylaws and other organizational documents of Borrower delivered to Lender on the date hereof remain true, accurate and complete and have not been amended, supplemented or
restated and are and continue to be in full force and effect; 
 (d) the execution and delivery by Borrower of this
Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized by all necessary corporate action on the part of Borrower; 
 (e) this Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting
creditors’ rights; and 
 (f) as of the date hereof, it has no defenses against the obligations to pay any amounts
under the Obligations. Borrower acknowledges that Lender has acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this Amendment and in connection with the Loan Documents.

 Borrower understands and acknowledges that Lender is entering into this Amendment in reliance upon, and in partial
consideration for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate. 
 4.
LIMITATION. The amendments set forth in this Amendment shall be limited precisely as written and shall not be deemed (a) to be a waiver or modification of any other term or condition of the Loan Agreement or
of any other instrument or agreement referred to therein or to prejudice any right or remedy which Lender may now have or may have in the future under or in connection with the Loan Agreement or any instrument or agreement referred to therein; or
(b) to be a consent to any future amendment or modification or waiver to any instrument or agreement the execution and delivery of which is consented to hereby, or to any waiver of any of the provisions thereof. Except as expressly amended
hereby, the Loan Agreement shall continue in full force and effect. 
 5. EFFECTIVENESS. This
Amendment shall become effective upon the satisfaction of all the following conditions precedent: 
 5.1
Amendment. Borrower and Lender shall have duly executed and delivered this Amendment to Lender. 

 5.2 Payment of Amendment Charge. Borrower shall have paid to Lender the
amendment charge referenced in Section 2 of this Amendment. 
 6. COUNTERPARTS. This
Amendment may be signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument. All counterparts shall be deemed an
original of this Amendment. 
 7. INTEGRATION. This Amendment and any documents executed in
connection herewith or pursuant hereto contain the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations, oral or written, with respect thereto and
no extrinsic evidence whatsoever may be introduced in any judicial or arbitration proceeding, if any, involving this Amendment; except that any financing statements or other agreements or instruments filed by Lender with respect to Borrower shall
remain in full force and effect. 
 8. GOVERNING LAW; VENUE. THIS AMENDMENT SHALL
BE GOVERNED BY AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA. Borrower and Lender each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California. 

[signature page follows] 

 IN WITNESS WHEREOF, the parties have
duly authorized and caused this Amendment to be executed as of the date first written above. 
  

			
	BORROWER:
	
	ELIXIR PHARMACEUTICALS, INC.
		
	By:	 	/s/ William K. Heiden
	Name:	 	William K. Heiden
	Title:	 	President and CEO

  

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	/s/ K. Nicholas Martitsch
	Name:	 	K. Nicholas Martitsch
	Title:	 	Associate General Counsel

  

			
	LENDER:
	
	HERCULES TECHNOLOGY II, L.P.,
a Delaware limited partnership
		
	By:	 	Hercules Technology SBIC Management, LLC,
		 	its General Partner
		
	By:	 	 Hercules Technology Growth Capital, Inc.,
 its Manager

		
	By:	 	/s/ K. Nicholas Martitsch
	Name:	 	K. Nicholas Martitsch
	Title:	 	Associate General Counsel

 Annex A 
 Updates to the Disclosure Schedules 

 Updated Schedule 5.13 
 Employee Loans 
  

	1.	Promissory Note from William Heiden to Elixir Pharmaceuticals, Inc. dated September 17, 2004 in the amount of $400,000. Elixir has forgiven $266,667 of the total amount and
$133,333 remains due. 

  

	2.	Promissory Note from a former executive of Elixir Pharmaceuticals, Inc. in the amount of $700,000. This note is currently not being repaid and thus Borrower has reserved against the
entire amount. 

  

	3.	From time to time Borrower makes advances in immaterial amounts to its employees to cover small business expenses. 

 Updated Schedule 5.14 
 Authorized Capital Stock 
 The authorized capital stock of the Corporation consists of (i) 200,000,000 shares of common stock, $0.001
par value per share (the “Common Stock”), 8,669,791 of which are issued and outstanding and (ii) 126,065,076 shares of preferred stock, $0.001 par value per share, of which (A) 13,595,558 shares have been designated as
Series A Convertible Preferred Stock, 13,479,998 of which are issued and outstanding and 115,560 of which are issuable upon exercise of outstanding warrants, (B) 300,000 shares have been designated as Series A-2 Convertible Preferred Stock, all
of which are issued and outstanding, (C) 43,523,745 shares have been designated as Series B Convertible Preferred Stock, all of which are issued or outstanding, (D) 1,000,000 have been designated as Series B-1 Convertible Preferred Stock,
all of which are issued and outstanding, (E) 460,933 shares have been designated as Series B-2 Convertible Preferred Stock, all of which are issued and outstanding, (F) 32,184,840 shares have been designated as Series C Convertible
Preferred Stock, 31,295,240 of which are issued and outstanding and 889,600 of which are issuable upon exercise of outstanding warrants, and (G) 35,000,000 shares have been designated as Series D Convertible Preferred Stock, 28,030,032 of which
are issued or outstanding. The Corporation has reserved an aggregate of 23,406,479 shares of Common Stock for issuance in the future under the Corporation Stock Option Plans. 
 Stockholders of Record 
 A revised capitalization table is attached hereto as Annex B and is incorporated by
reference into this section in its entirety. 
  

 2 

 Annex B 
 Capitalization Table 
  

 3 

 UPDATED EXHIBIT D 
 BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 
 Registered Copyrights 
 None. 
 Registered Trademarks 
 Trademark Records By Trademark 
  

															
	 Owner
	  	 Trademark
	  	 Country
	  	Application
No.	  	Registration
No	  	Registration
Date	  	Classes	  	Status
	 BRIAFAST
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	BRIAFAST	  	USA	  	77047378	  		  		  	5	  	Pending
	 BRIAGLIDE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	BRIAGLIDE	  	USA	  	77047381	  		  		  	5	  	Pending
	 BRIAMET
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	BRIAMET	  	USA	  	77047383	  		  		  	5	  	Pending
	 BRIAVANCE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	BRIAVANCE	  	USA	  	77047382	  		  		  	5	  	Pending
	 E DESIGN
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc. 
	  	E DESIGN	  	USA	  	78203665	  	2,844,776	  	May 25 2004	  	42	  	Registered
	 Elixir Pharmaceuticals, Inc. 
	  	E DESIGN	  	Canada	  	1,184,377	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc. 
	  	E DESIGN	  	CTM	  	003258861	  	003258861	  	Apr 11 2005	  	5,35,42	  	Registered
	 Elixir Pharmaceuticals, Inc. 
	  	E DESIGN	  	Australia	  	961799	  	961,799	  	Jul 15 2003	  	5,42	  	Registered
	 ELIXIR PHARMACEUTICALS
	  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc. 
	  	ELIXIR PHARMACEUTICALS	  	USA	  	78203638	  	2,864,893	  	Jul 20 2004	  	42	  	Registered

															
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Argentina	  	2,664,641	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Brazil	  	827,219,598	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	China	  	4,551,353	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Hong Kong	  	300378487	  	300378487	  	Mar 2 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	India	  	1342455	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	New Zealand	  	726,041	  	726,041	  	Sep 8 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Norway	  	2005/01849	  	234,380	  	Aug 17 2006	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	USA	  	78203617	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	CTM	  	003258829	  	003258829	  	Nov 7 2005	  	5,35,42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Australia	  	1,042,330	  		  		  	5,42	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS	  	Canada	  	1,184,375	  		  		  	5,42	  	Pending
	 ELIXIR PHARMACEUTICALS & E des
	  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	USA	  	78203655	  	2,871,472	  	Aug 10 2004	  	42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	Japan	  	2006-64861	  		  		  	5	  	Pending

  

 2 

															
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	Mexico	  	822180	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	Switzerland	  		  	535,365	  		  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	USA	  	78203628	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	CTM	  	003258845	  	003258845	  	Sep 26 2005	  	5,35,42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	Australia	  	961800	  	961,800	  	Jul 15 2003	  	5,42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	ELIXIR
PHARMACEUTICALS
& E des	  	Canada	  	1,184,376	  		  		  	5,42	  	Pending
	 GLUFAST
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	GLUFAST	  	Brazil	  	827814631	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	GLUFAST	  	Canada	  	1,274,820	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	GLUFAST	  	CTM	  	4662987	  	4662987	  	Sep 21 2006	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	GLUFAST	  	Mexico	  	742959	  	907644	  	Oct 31 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	GLUFAST	  	USA	  	78723450	  		  		  	5	  	Pending
	 KIRAGLIDE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	KIRAGLIDE	  	USA	  	77035906	  		  		  	5	  	Pending
	 KIRAMET
	  		  		  		  		  		  		  	

  

 3 

															
	 Elixir Pharmaceuticals, Inc.
	  	KIRAMET	  	USA	  	77035908	  		  		  	5	  	Pending
	 KIRAVANCE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	KIRAVANCE	  	USA	  	77035907	  		  		  	5	  	Pending
	 KIRFAST
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	KIRFAST	  	USA	  	77035905	  		  		  	5	  	Pending
	 NEXAFAST
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	NEXAFAST	  	USA	  	77047385	  		  		  	5	  	Pending
	 NEXAGLIDE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	NEXAGLIDE	  	USA	  	77047387	  		  		  	5	  	Pending
	 NEXAMET
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	NEXAMET	  	USA	  	77047390	  		  		  	5	  	Pending
	 NEXAVANCE
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	NEXAVANCE	  	USA	  	77047388	  		  		  	5	  	Pending
	 NUTRACENT
	  		  		  		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	Argentina	  	2664640	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	Brazil	  	827,487,452	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	China	  	4,551,352	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	Hong Kong	  	300378478	  	300,378,478	  	Mar 2 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	India	  	1,342,456	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	Mexico	  	831848	  		  		  	5	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	New Zealand	  	726,042	  	726,042	  	Sep 8 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	  	Norway	  	2005/01848	  	229883	  	Dec 5 2005	  	5	  	Registered

  

 4 

															
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Republic of
Korea (South)	 	40-2005- 9459	  	659476	  	Apr 21 2006	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Singapore	 	T05/02665G	  	T05/02665G	  	Sep 27 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Switzerland	 	2005 629	  	534,586	  	Jun 29 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Taiwan	 	094013646	  	1,179,333	  	Nov 1 2005	  	5	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Australia	 	1025396	  	1,025,396	  	Oct 15 2004	  	5,42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Canada	 	1,234,668	  		  		  	5,42	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	CTM	 	004070355	  	004070355	  		  	5,42	  	Pending
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	Japan	 	2004-094483	  	4,847,992	  	Mar 18 2005	  	5,42	  	Registered
	 Elixir Pharmaceuticals, Inc.
	  	NUTRACENT	 	USA	 	78/403,395	  		  		  	5,42	  	Pending
	 THE SCIENCE OF OPTIMAL AGING
	 		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	THE SCIENCE OF
OPTIMAL AGING	 	USA	 	78575907	  		  		  	5	  	Pending
	 ZENOFAST
	  		 		 		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	ZENOFAST	 	USA	 	77035909	  		  		  	5	  	Pending
	 ZENOGLIDE
	  		 		 		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	ZENOGLIDE	 	USA	 	77035911	  		  		  	5	  	Pending
	 ZENOMET
	  		 		 		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	ZENOMET	 	USA	 	77035913	  		  		  	5	  	Pending
	 ZENOVANCE
	  		 		 		  		  		  		  	
	 Elixir Pharmaceuticals, Inc.
	  	ZENOVANCE	 	USA	 	77035912	  		  		  	5	  	Pending

  

			
		
	TM Administrator - END OF REPORT	  	IPPO WebTMS: printed Aug 17 2007 21:30

  

 5 

 Patents and Patent Applications 
 The Company owns or controls the patent and patent applications listed in the table below and pursuant to the license agreements set forth on Schedule 3.9(m) of the Schedule of Exceptions. 
 1. Assignee ELIXIR – Elixir owns the listed patent/application. 
 2. Assignee MIT – Elixir has exclusively licensed the patent/application from the Massachusetts Institute of Technology. 
 3. Assignee Northwestern – Elixir has exclusively licensed the patent/application from Northwestern University. 
 4. Assignee UCSF (Kenyon) – Elixir has exclusively licensed the patent/application from UCSF through the Regents of the University of California. The technology was developed in the laboratory of Cynthia Kenyon.

 5. Assignee BMS – Elixir has exclusively licensed the patent/application from Bristol-Myers Squibb Company. 
 6. Assignee MCG – Elixir has exclusively licensed the patent/application from the Medical College of Georgia. 
 7. Assignee UCSF (Verdin) – Elixir has exclusively licensed the patent/application from UCSF through the Regents of the University of California.
The technology was developed in the laboratory of Eric Verdin. 
 8. Assignee BIDMC/CMCC – Elixir has exclusively licensed the
patent/application from co-owners Beth Israel Deaconess Medical Center and Children’s Medical Center. 
 9. Assignee Kissei- Elixir has
exclusively licensed the patent/application form Kissei Pharmaceutical Company. 
  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 EP
	  	ELIXIR	  	03813446.6	  		  	1573324	  	Cytochrome C
Acetylation	  	ABANDONED	  	12/15/2003	  	9 /14/2005	  		  	13407-
026EP1
	 US
	  	ELIXIR	  	10/538,823	  		  	US 2006-0051767 A1	  	Cytochrome C
Acetylation	  	PUBLISHED	  	6/13/2005	  	3 /9 /2006	  		  	13407-
026US1
	 WO
	  	ELIXIR	  	PCT/US03/39794	  		  	WO2004/055169	  	Cytochrome C
Acetylation	  	NAT PHASE	  	12/15/2003	  	7 /1 /2004	  		  	13407-
026WO1
	 EP
	  	ELIXIR	  	04703016.8	  		  	1587951	  	Substrate Detection
Assay	  	ABANDONED	  	1/16/2004	  	10/26/2005	  		  	13407-
029EP1
	 US
	  	ELIXIR	  	11/181,453	  		  	US 2006-0292652 A1	  	Substrate Detection
Assay	  	ABANDONED	  	7/13/2005	  	12/28/2006	  		  	13407-
060001
	 WO
	  	ELIXIR	  	PCT/US2004/01239	  		  	WO2004/064739	  	Substrate Detection
Assay	  	NAT PHASE	  	1/16/2004	  	8 /5 /2004	  		  	13407-
029WO1
	 US
	  	ELIXIR	  	10/562,389	  		  	US-2007-0105109-A1	  	SirT1 And Genetic
Disorders	  	PUBLISHED	  	12/27/2005	  	5 /10/2007	  		  	13407-
039US1

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 WO
	  	ELIXIR	  	PCT/US2004/021189	  		  	WO2005/004814	  	SirT1 And Genetic
Disorders	  	NAT PHASE	  	7/1 /2004	  	1/20/2005	  		  	13407-
039WO1
	 AU
	  	ELIXIR	  	2003272287	  		  		  	Regulation Of The
Growth Hormone/
Igf-1 Axis	  	PENDING	  	9/8 /2003	  		  		  	13407-
020AU1
	 CA
	  	ELIXIR	  	2497826	  		  		  	Regulation Of The
Growth Hormone/
Igf-1 Axis	  	PENDING	  	9/8 /2003	  		  		  	13407-
020CA1
	 EP
	  	ELIXIR	  	03754463.2	  		  	1546389	  	Regulation Of The
Growth Hormone/
Igf-1 Axis	  	PUBLISHED	  	9/8 /2003	  	6/29/2005	  		  	13407-
020EP1
	 US
	  	ELIXIR	  	10/656,530	  		  	US-2004-0121407-A1	  	Regulation Of The
Growth Hormone/
Igf-1 Axis	  	PUBLISHED	  	9/5 /2003	  	6/24/2004	  		  	13407-
020001
	 WO
	  	ELIXIR	  	PCT/US03/28096	  		  	WO2004-022005	  	Regulation Of The
Growth Hormone/
Igf-1 Axis	  	NAT PHASE	  	9/8 /2003	  	3/18/2004	  		  	13407-
020WO1
	 US
	  	ELIXIR	  	10/982,997	  		  	US-2005-0187237-A1	  	Therapeutic
Compounds And
Uses Thereof	  	PUBLISHED	  	11/4 /2004	  	8/25/2005	  		  	13407-
046001
	 CA
	  	ELIXIR	  	2550091	  		  		  	Methods Of Treating
A Disorder	  	PENDING	  	12/20/2004	  		  		  	13407-
052CA1
	 EP
	  	ELIXIR	  	04815304.3	  		  	1694323	  	Methods Of Treating
A Disorder	  	PUBLISHED	  	12/20/2004	  	8/30/2006	  		  	13407-
052EP1
	 JP
	  	ELIXIR	  	2006-545607	  		  		  	Methods Of Treating
A Disorder	  	PUBLISHED	  	12/20/2004	  	6/18/2007	  		  	13407-
052JP1
	 MX
	  	ELIXIR	  	PA/A/2006/007054	  		  		  	Methods Of Treating
A Disorder	  	PENDING	  		  		  		  	13407-
052MX1
	 AU
	  	ELIXIR	  	2005208934	  		  		  	Treating A Viral
Disorder	  	PENDING	  	1/31/2005	  		  		  	13407-
051AU1
	 CA
	  	ELIXIR	  	2553814	  		  		  	Treating A Viral
Disorder	  	PENDING	  	1/31/2005	  		  		  	13407-
051CA1
	 EP
	  	ELIXIR	  	05712266.5	  		  	1734950	  	Treating A Viral
Disorder	  	PUBLISHED	  	1/31/2005	  		  		  	13407-
051EP1

  

																					
	 COUNTRY
	  	ASSIGNEE	 	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 JP
	  	ELIXIR	 	2006-551509	  		  		  	Treating A Viral
Disorder	  	PENDING	  	1/31/2005	  		  		  	13407-
051JP1
	 CA
	  	ELIXIR	 	2561801	  		  		  	Sulfonamides And
Uses Thereof	  	PENDING	  	4/4/2005	  		  		  	13407-
056CA1
	 EP
	  	ELIXIR	 	05733046.6	  		  	1789409	  	Sulfonamides And
Uses Thereof	  	PUBLISHED	  	4/4/2005	  		  		  	13407-
056EP1
	 JP
	  	ELIXIR	 	2007-506356	  		  		  	Sulfonamides And
Uses Thereof	  	PENDING	  	4/4/2005	  		  		  	13407-
056JP1
	 AU
	  	ELIXIR	 	2005277389	  		  		  	Growth-Hormone
Secretagogues	  	PENDING	  	8/18/2005	  		  		  	13407-
063AU1
	 CA
	  	ELIXIR	 	2576915	  		  		  	Growth-Hormone
Secretagogues	  	PENDING	  	8/18/2005	  		  		  	13407-
063CA1
	 EP
	  	ELIXIR	 	05786392.0	  		  	1781311	  	Growth-Hormone
Secretagogues	  	PUBLISHED	  	8/18/2005	  		  		  	13407-
063EP1
	 JP
	  	ELIXIR	 	N/A	  		  		  	Growth-Hormone
Secretagogues	  	PENDING	  		  		  		  	13407-
063JP1
	 US
	  	ELIXIR	 	11/451,086	  		  	US 2006-0293370 A1	  	Sulfonamide
Compounds And
Uses Thereof	  	PUBLISHED	  	6/12/2006	  		  		  	13407-
082001
	 AU
	  	MIT	 	2002320325	  		  		  	Sir2 Activity	  	TRANSFER	  	7 /8 /2002	  		  		  	13407-
015AU1
	 WO
	  	MIT	 	PCT/US02/021461	  		  	wo03/004621	  	Sir2 Activity	  	TRANSFER	  	7 /8 /2002	  	1/16/2003	  		  	13407-
015WO1
	 US
	  	MIT	 	11/155,025	  		  		  	Sir2 Activity	  	TRANSFER	  	6/15/2005	  		  		  	13407-
015004
	 US
	  	MIT	 	11/409,170	  		  	US-2007-0099830-A1	  	Sirt4 Activities	  	PUBLISHED	  	4/21/2006	  		  		  	13407-
087001
	 AU
	  	UCSF (Kenyon)	 	2002350597	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  	6/24/2002	  		  		  	

  

																					
	 COUNTRY
	  	ASSIGNEE	 	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 CA
	  	UCSF (Kenyon)	 	2451247	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  	6/24/2002	  		  		  	
	 EP
	  	UCSF
(Kenyon)	 	2752095.6	  		  	1406489	  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PUBLISHED	  	6/24/2002	  	4/14/2004	  		  	
	 WO
	  	UCSF
(Kenyon)	 	US02/020247	  		  	379,425	  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PUBLISHED	  	6/24/2002	  	1/3/2003	  		  	
	 US
	  	UCSF
(Kenyon)	 	11/282262	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  	11/18/2005	  		  		  	
	 WO
	  	UCSF
(Kenyon)	 	US03/25266	  		  	WO2004/015087	  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PUBLISHED	  	8/11/2003	  	2/19/2004	  		  	
	 US
	  	UCSF
(Kenyon)	 	10/536,635	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  	5/26/2005	  		  		  	
	 AU
	  	UCSF
(Kenyon)	 	2003256408	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  		  		  		  	
	 CA
	  	UCSF
(Kenyon)	 	2494066	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  		  		  		  	
	 EP
	  	UCSF
(Kenyon)	 	03785239.9	  		  		  	Eukaryotic Genes
Involved In Adult
Lifespan Regulation	  	PENDING	  		  		  		  	
	 US
	  	MIT	 	09/461,580	  		  	US-2003-0207325-A1	  	Methods For Identifying
Agents Which Alter
Histone Protein
Acetylation, Decrease
Aging, Increase
Lifespan	  	PUBLISHED	  	12/15/1999	  	11/6/2003	  		  	13407-
016001

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 US
	  	MIT	  	09/735,786	  		  		  	Methods For Identifying
Agents Which Alter
Histone Protein
Acetylation, Decrease
Aging, Or Increase
Lifespan	  	PENDING	  	12/13/2000	  		  		  	13407-
016002
	 US
	  	MIT	  	09/826,752	  	6,787,300	  		  	Identifying Lifespan-
Altering Agents	  	ISSUED	  	4 /5 /2001	  	10/4/2001	  	9 /7/2004	  	13407-
017005
	 US
	  	MIT	  	09/826,752	  	6,787,300	  		  	Identifying Lifespan-
Altering Agents	  	ISSUED	  	4 /5 /2001	  	10/4/2001	  	9 /7/2004	  	13407-
017005
	 US
	  	MIT	  	08/396,001	  	5,919,618	  		  	Genes Determining
Cellular Senescence In
Yeast	  	ISSUED	  	2 /28/1995	  		  	7 /6 /1999	  	13407-
017002
	 US
	  	MIT	  	09/323,433	  	6,218,512	  		  	Genes Determining
Cellular Senescence In
Yeast	  	ISSUED-B	  	6 /1 /1999	  		  	4/17/2001	  	13407-
017003
	 US
	  	MIT	  	08/861,464	  	5,874,210	  		  	Genes Determining
Cellular Senescence In
Yeast	  	ISSUED	  	5 /22/1997	  		  	2/23/1999	  	13407-
017004
	 US
	  	MIT	  	10/912,434	  		  	US-2005-0009169-A1	  	Genes Determining
Cellular Senescence In
Yeast	  	ABANDONED	  	8 /5 /2004	  	1/13/2005	  		  	13407-
017006
	 WO
	  	ELIXIR	  	PCT/US03/38628	  		  	WO2004/050898	  	AMPK Pathway
Components	  	NAT PHASE	  	12/4 /2003	  	6/17/2004	  		  	13407-
025WO1
	 US
	  	Northwestern	  	10/891,929	  		  		  	Reducing
Polyglutamine-Based
Aggregation	  	PENDING	  	7 /14/2004	  		  		  	13407-
043001
	 CA
	  	Northwestern	  	2435136	  		  		  	Reducing
Polyglutamine-Based
Aggregation	  	PENDING	  	7 /15/2003	  		  		  	13407-
043CA1

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 US
	  	ELIXIR	  	10/940,269	  		  	US 2005-0209300 A1	  	Methods Of Treating A
Disorder	  	ABANDONED	  	9 /13/2004	  	9 /22/2005	  		  	13407-
044001
	 CA
	  	ELIXIR	  	2538759	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2004	  		  		  	13407-
044CA1
	 EP
	  	ELIXIR	  	04788727.8	  		  	1677794	  	Methods Of Treating A
Disorder	  	PUBLISHED	  	9/13/2004	  	7/12/2006	  		  	13407-
044EP1
	 JP
	  	ELIXIR	  	2006-526388	  		  	2007-505148	  	Methods Of Treating A
Disorder	  	PUBLISHED	  		  	3/8/2007	  		  	13407-
044JP1
	 WO
	  	ELIXIR	  	PCT/US2004/029942	  		  	WO2005/026112	  	Methods Of Treating A
Disorder	  	NAT PHASE	  	9 /13/2004	  	3 /24/2005	  		  	13407-
044WO1
	 WO
	  	ELIXIR	  	PCT/US2004/036870	  		  	WO2005/046682	  	Therapeutic Compounds
And Uses Thereof	  	NAT PHASE	  	11/4 /2004	  	5 /26/2005	  		  	13407-
046WO1
	 CA
	  	ELIXIR	  	2544602	  		  		  	Therapeutic Compounds
And Uses Thereof	  	PENDING	  	11/4 /2004	  		  		  	13407-
046CA1
	 CN
	  	ELIXIR	  	200480039713.3	  		  	CN1901908A	  	Therapeutic Compounds
And Uses Thereof	  	PUBLISHED	  	11/4/2004	  	1 /24/2007	  		  	13407-
046CN1
	 EP
	  	ELIXIR	  	04800764.5	  		  	1682136	  	Therapeutic Compounds
And Uses Thereof	  	PUBLISHED	  	11/4/2004	  	7/26/2006	  		  	13407-
046EP1
	 IN
	  	ELIXIR	  	2346/DELNP/2006	  		  		  	Therapeutic Compounds
And Uses Thereof	  	PENDING	  	11/4/2004	  		  		  	13407-
046IN1
	 JP
	  	ELIXIR	  	2006-538496	  		  	2007-510662	  	Therapeutic Compounds
And Uses Thereof	  	PUBLISHED	  	11/4/2004	  	4/26/2007	  		  	13407-
046JP1
	 MX
	  	ELIXIR	  	PA/A/2006/005038	  		  		  	Therapeutic Compounds
And Uses Thereof	  	PENDING	  	11/4/2004	  		  		  	13407-
046MX1
	 WO
	  	BIDMC/
CMCC	  	US01/25099	  		  	WO2002/014552	  	Genetic Loci indicative
of propensity for
longevity and methods
for identifying
propensity for age-
related disease	  	PUBLISHED	  	8/10/2001	  	2/21/2002	  		  	Not ours
	 US
	  	ELIXIR	  	11/047,757	  		  	US 2005-0256181 A1	  	Treating A Viral
Disorder	  	PUBLISHED	  	1 /31/2005	  		  		  	13407-
051001
	 WO
	  	ELIXIR	  	PCT/US2005/002755	  		  	WO2005/072408	  	Treating A Viral
Disorder	  	NAT PHASE	  	1 /31/2005	  	8 /11/2005	  		  	13407-
051WO1
	 US
	  	ELIXIR	  	11/018,018	  		  	US-2005-0250794-A1	  	Methods Of Treating A
Disorder	  	PUBLISHED	  	12/20/2004	  	11/10/2005	  		  	13407-
052001
	 WO
	  	ELIXIR	  	PCT/US2004/043207	  		  	WO2005/060711	  	Methods Of Treating A
Disorder	  	NAT PHASE	  	12/20/2004	  	7 /7 /2005	  		  	13407-
052WO1

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 WO
	  	ELIXIR	  	PCT/US2004/042907	  		  	WO2005/062849	  	Lifespan Management	  	NAT PHASE	  	12/20/2004	  	7/14/2005	  		  	13407-
053WO1
	 US
	  	ELIXIR	  	10/583,187	  		  		  	Lifespan Management	  	PENDING	  	6 /16/2006	  		  		  	13407-
053US1
	 US
	  	ELIXIR	  	11/048,490	  		  	US 2006-0019952 A1	  	Anti-Viral Therapeutics	  	PUBLISHED	  	1 /31/2005	  		  		  	13407-
054001
	 WO
	  	ELIXIR	  	PCT/US2005/002897	  		  	WO2005/072412	  	Anti-Viral Therapeutics	  	NAT PHASE	  	1 /31/2005	  	8/11/2005	  		  	13407-
054WO1
	 AU
	  	ELIXIR	  	2005208938	  		  	1715855	  	Anti-Viral Therapeutics	  	PUBLISHED	  		  		  		  	13407-
054AU1
	 CA
	  	ELIXIR	  	2553670	  		  		  	Anti-Viral Therapeutics	  	PENDING	  		  		  		  	13407-
054CA1
	 EP
	  	ELIXIR	  	05712361.4	  		  		  	Anti-Viral Therapeutics	  	PENDING	  		  		  		  	13407-
054EP1
	 JP
	  	ELIXIR	  	2006-551523	  		  		  	Anti-Viral Therapeutics	  	PENDING	  		  		  		  	13407-
054CA1
	 US
	  	ELIXIR	  	11/098,315	  		  	US 2005-0261332 A1	  	Sulfonamides And
Uses Thereof	  	PUBLISHED	  	4 /4 /2005	  		  		  	13407-
056001
	 WO
	  	ELIXIR	  	PCT/US2005/011357	  		  	WO 2005/097788 A3	  	Sulfonamides And
Uses Thereof	  	NAT PHASE	  	4 /4 /2005	  		  		  	13407-
056WO1
	 US
	  	ELIXIR	  	11/145,471	  		  	US-2006-0147947-A1	  	AMPK Pathway
Components	  	PUBLISHED	  	6 /3 /2005	  	7/6/2006	  		  	13407-
057001
	 US
	  	MIT	  	10/885,977	  		  	US 2005-0136429 A1	  	Sirt1 Modulation Of
Adipogenesis And
Adipose Function	  	PUBLISHED	  	7 /6 /2004	  	6/23/2005	  		  	13407-
058001
	 WO
	  	MIT	  	PCT/US2004/021630	  		  	WO2005/002527	  	Sirt1 Modulation Of
Adipogenesis And
Adipose Function	  	ABANDONED	  	7 /6 /2004	  	1/13/2005	  		  	13407-
058WO1
	 WO
	  	ELIXIR	  	PCT/US2005/029335	  		  	WO 2006/23608 A2	  	Growth-Hormone
Secretagogues	  	NAT PHASE	  	8 /18/2005	  		  		  	13407-
063WO1

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 US
	  	ELIXIR	  	11/227,696	  		  	US 2006-0193845 A1	  	Combination Therapy
For Controlled Carbohydrate
Digestion	  	PUBLISHED	  	9/14/2005	  		  		  	13407-
064001
	 CN
	  	ELIXIR	  	200580030897.1	  		  		  	Combination Therapy For
Controlled Carbohydrate
Digestion	  	PENDING	  		  		  		  	13407-
064CN1
	 EP
	  	ELIXIR	  	05800889.7	  		  	1796687	  	Combination Therapy For
Controlled Carbohydrate
Digestion	  	PUBLISHED	  		  		  		  	13407-
064EP1
	 JP
	  	ELIXIR	  	N/A	  		  		  	Combination Therapy For
Controlled Carbohydrate
Digestion	  	PENDING	  		  		  		  	13407-
064JP1
	 WO
	  	ELIXIR	  	PCT/US2005/033098	  		  	WO 2006/032011	  	Combination Therapy For
Controlled Carbohydrate
Digestion	  	NAT PHASE	  	9/14/2005	  		  		  	13407-
064WO1
	 WO
	  	ELIXIR	  	PCT/US2005/034522	  	WO 2006/036932	  		  	Sulfonamides And Uses
Thereof	  	NAT PHASE	  	9/27/2005	  		  		  	13407-
067WO1
	 US
	  	ELIXIR	  	11/077,664	  		  	US 2006-0074124 A1	  	Methods Of Treating A
Disorder	  	PUBLISHED	  	3/11/2005	  	4/6/2006	  		  	13407-
092001
	 AU
	  	ELIXIR	  	2005284851	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092AU1
	 CA
	  	ELIXIR	  	2578355	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092CA1
	 CN
	  	ELIXIR	  	200580033718.X	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092CN1
	 EP
	  	ELIXIR	  	05803803.5	  		  	1793817	  	Methods Of Treating A
Disorder	  	PUBLISHED	  	9/13/2005	  	6/13/2007	  		  	13407-
092EP1
	 IN
	  	ELIXIR	  	1969/DELNP/2007	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092IN1
	 JP
	  	ELIXIR	  	N/A	  		  		  	Methods Of Treating A
Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092JP1

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 MX
	  	ELIXIR	  	MX/a/2007/002816	  		  		  	Methods Of Treating
A Disorder	  	PENDING	  	9/13/2005	  		  		  	13407-
092MX1
	 WO
	  	ELIXIR	  	PCT/US2005/032760	  		  	WO 2006/031894	  	Methods Of Treating
A Disorder	  	NAT PHASE	  	9 /13/2005	  	3/23/2006	  		  	13407-
092WO1
	 WO
	  	ELIXIR	  	PCT/US2006/035761	  		  	WO2007/033292	  	Combination Therapy
For Controlled
Carbohydrate
Digestion	  	PUBLISHED	  	9/13/2006	  		  		  	13407-
110WO1
	 US
	  	ELIXIR	  	11/557,377	  		  		  	Combinations of
Metformin and
Mitiglinide	  	PENDING	  	11/7 /2006	  		  		  	13407-
112001
	 WO
	  	ELIXIR	  	PCT/US2006/043376	  		  	WO2007/056387	  	Combinations of
Metformin and
Mitiglinide	  	PUBLISHED	  	11/7 /2006	  		  		  	13407-
112WO1
	 US
	  	ELIXIR	  	60/866,363	  		  		  	PHARMACEUTICAL
COMPOSITIONS
AND METHODS	  	PENDING	  	11/17/2006	  		  		  	13407-
116P01
	 US
	  	ELIXIR	  	11/564,815	  		  		  	SULFONAMIDE
COMPOUNDS AND
USES THEREOF	  	PENDING	  	11/29/2006	  		  		  	13407-
117001
	 WO
	  	ELIXIR	  	PCT/US2007/070959	  		  		  	SULFONAMIDE
COMPOUNDS AND
USES THEREOF	  	PENDING	  	6 /12/2007	  		  		  	13407-
117WO1
	 WO
	  	MCG	  	US03/037054	  		  	WO2004/048925	  	NaCT as a target for
lifespan expansion and
weight reduction.	  	PUBLISHED	  	11/20/2003	  	6/10/2004	  		  	Not ours

  

																					
	 COUNTRY
	  	ASSIGNEE	 	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	 	F&R
Reference
	 US
	  	MCG	 	10/718359	  		  		  	NaCT as a target for
lifespan expansion and
weight reduction.	  	PUBLISHED	  	11/20/2003	  	5/5/2005	  		 	Not ours
	 EP
	  	MCG	 	0379 6430.1	  		  		  	NaCT as a target for
lifespan expansion and
weight reduction.	  	PENDING	  		  		  		 	Not ours
	 WO
	  	UCSF
(Verdin)	 	US03/15813	  		  	WO2003/099210	  	Methods of Modulating
Tubulin Deacetylase
Activity	  	PUBLISHED	  	5/20/2003	  	12/4/2003	  		 	Not ours
	 US
	  	UCSF
(Verdin)	 	10/441854	  		  		  	Methods of Modulating
Tubulin Deacetylase
Activity	  	PENDING	  	5/20/2003	  		  		 	Not ours
	 EP
	  	UCSF
(Verdin)	 	03726921.4	  		  		  	Methods of Modulating
Tubulin Deacetylase
Activity	  	PENDING	  		  		  		 	Not ours
	 AU
	  	UCSF
(Verdin)	 	2003237248	  		  		  	Methods of Modulating
Tubulin Deacetylase
Activity	  	PENDING	  		  		  		 	Not ours
	 CA
	  	UCSF
(Verdin)	 		  		  		  	Methods of Modulating
Tubulin Deacetylase
Activity	  	PENDING	  		  		  	(274)	 	Not ours
	 CA
	  	UCSF
(Verdin)	 	2484013	  		  		  	Methods of Modulating
Mitochondrial NAD-
Dependent Deacetylase	  	PENDING	  	5/22/2003	  		  		 	Not ours
	 AU
	  	UCSF
(Verdin)	 	2003237248	  		  		  	Methods of Modulating
Mitochondrial NAD-
Dependent Deacetylase	  	PENDING	  		  		  		 	Not ours
	 EP
	  	UCSF (Verdin)	 	03736714.1	  		  		  	Methods of Modulating
Mitochondrial NAD-
Dependent Deacetylase	  	PENDING	  		  		  		 	Not ours

  

																					
	 COUNTRY
	  	ASSIGNEE	 	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	 	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 WO
	  	UCSF
(Verdin)	 	US03/16499	  		  		  	Methods of Modulating
Mitochondrial
NAD-Dependent
Deacetylase	  	PENDING	 	5/22/2003	  		  		  	Not ours
	 US
	  	UCSF
(Verdin)	 	10/444633	  		  		  	Methods of Modulating
Mitochondrial NAD-
Dependent Deacetylase	  	PENDING
[ALLOWED
CASE]	 	5/22/2003	  		  		  	Not ours
	 US
	  	UCSF
(Verdin)	 	11/839,292	  		  		  	Methods of Modulating
Mitochondrial NAD-
Dependent Deacetylase	  	PENDING	 	9/15/2007	  		  		  	Not ours
	 WO
	  	UCSF
(Verdin)	 	US04/043423	  		  	WO2005/062952	  	Compositions and
Methods for
Modulating Sirtuin
Activity	  	PUBLISHED	 	12/22/2004	  	7/14/2005	  		  	Not ours
	 US
	  	UCSF
(Verdin)	 	11/022,192	  		  		  	Compositions and
Methods for
Modulating Sirtuin
Activity	  	PENDING	 		  		  		  	Not ours
	 EP
	  	UCSF
(Verdin)	 	04815492.6	  		  		  	Compositions and
Methods for
Modulating Sirtuin
Activity	  	PENDING	 		  		  		  	Not ours
	 CA
	  	UCSF (Verdin)	 	2550157	  		  		  	Compositions and
Methods for
Modulating Sirtuin
Activity	  	PENDING	 		  		  		  	Not ours
	 WO
	  	BMS	 	US/03/027513	  		  	WO2004/021984	  	Heterocyclic Aromatic
Compounds Useful As
Growth Hormone
Secretagogues	  	PUBLISHED	 	9/2/2003	  	3/18/2004	  		  	Not F&R
	 US
	  	BIDMC/
 CMCC
	 	09/928102	  	6673546	  		  	Genetic Loci indicative
of propensity for
longevity and methods
for identifying
propensity for age-
related disease	  	ISSUED	 	8/10/2001	  		  	1/6/2004	  	

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 US
	  	Kissei	  	07/860023	  	5202335	  		  	Succinic acid
compounds	  	ISSUED	  		  	3/30/1992	  	4/13/1993	  	
	 US
	  	Kissei	  	09/979149	  		  		  	Immediate release
medicinal
compositions for
oral use	  	PENDING	  		  	5/21/1999	  		  	
	 US
	  	Kissei	  	10/817898	  		  	US-2004-0192755	  	Immediate release
medicinal
compositions for
oral use	  	PENDING	  	9/30/2004	  	4/6/2004	  		  	
	 US
	  	Kissei	  	10/817902	  		  	US-2004-0197400	  	Immediate release
medicinal
compositions for
oral use	  	PENDING	  	1/17/2004	  	4/6/2004	  		  	
	 US
	  	Kissei	  	10/519102	  		  		  	Drug composition
for blood sugar
control	  	PENDING	  		  		  		  	
	 US
	  	Kissei	  	10/519155	  		  		  	Drug composition
for prevention or
inhibition of
advance of
diabetic
complication	  	PENDING	  		  		  		  	

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB DATE	  	ISSUE
DATE	  	F&R
Reference
	 Canada
	  	Kissei	  	2062877	  	2062877	  		  		  		  		  	3/30/1992	  		  	
	 Canada
	  	Kissei	  	2373962	  		  		  		  		  		  		  		  	
	 Canada
	  	Kissei	  	2490250	  		  		  		  		  		  		  		  	
	 Canada
	  	Kissei	  	2489660	  		  		  		  		  		  		  		  	
	 Mexico
	  	Kissei	  	PA/a/2001/011898	  		  		  		  		  		  		  		  	
	 Brazil
	  	Kissei	  	PI-9917315-8	  		  		  		  		  		  		  		  	

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	 FILING
DATE
	  	 PUB
DATE
	  	ISSUE
DATE	  	F&R
Reference
	 Brazil
	  	Kissei	  	PCT/FR98/01405	  		  		  	Process for the
preparation of a
substituted
perhydroisoindole	  		  	01/JUL/1998	  	03/OCT/2000	  		  	
	 Canada
	  	Kissei	  	PCT/FR98/01405	  	2,295,992	  		  	Process for the
preparation of a
substituted
perhydroisoindole	  		  	01/JUL/1998	  		  		  	
	 Mexico
	  	Kissei	  	PCT/FR98/01405	  	215091	  		  	Process for the
preparation of a
substituted
perhydroisoindole	  		  	01/JUL/1998	  		  		  	
	 PCT
	  	Kissei	  	PCT/FR98/01405	  		  		  	Process for the
preparation of a
substituted
perhydroisoindole	  		  	01/JUL/1998	  	14/JAN/1999	  		  	
	 USA
	  	Kissei	  	PCT/FR98/01405	  	6,133,454	  		  	Process for the
preparation of a
substituted
perhydroisoindole	  		  	01/JUL/1998	  		  		  	
	 Argentina
	  	Kissei	  	P010100820	  		  		  	New process for
the preparation of
isoindoline	  		  	23/FEB/2001	  	02/APR/2003	  		  	

  

																					
	 COUNTRY
	  	ASSIGNEE	  	SERIALNO	  	PATENTNO	  	PUBLNO	  	TITLE	  	STATUS	  	FILING
DATE	  	PUB
DATE	  	ISSUE
DATE	  	F&R
Reference
	 Brazil
	  	Kissei	  	PI0100757-2	  		  		  	New process for
the preparation
of isoindoline	  		  	23/FEB/2001	  	25/SEP/2001	  		  	
	 Canada
	  	Kissei	  	2,338,899	  		  		  	New process for
the preparation
of isoindoline	  		  	16/FEB/2001	  		  		  	
	 Mexico
	  	Kissei	  	2001/001921	  	216607	  		  	New process for
the preparation
of isoindoline	  		  	22/FEB/2001	  		  		  	
	 US
	  	Kissei	  	09/785,956	  	6,320,058	  		  	New process for
the preparation
of isoindoline	  		  	16/FEB/2001	  		  		  	

  

 License Agreements 
 Non-Exclusive License Agreement by and among Baylor College of Medicine and the Company, dated as of January 6, 2004. 
 Exclusive License Agreement by and among Beth Israel Deaconess Medical Center, Children’s Medical Center Corporation and Centagenetix, dated as of October 26, 2001. 
 Restatement and Amendment of Exclusive License Agreement by and among Boston Medical Center Corporation, Trustees of Boston University and the Company,
dated as of June 9, 2004. 
 Exclusive License Agreement by and between BMS and the Company, dated as of April 25, 2005 (the
“BMS Agreement”). 
 Exclusive License Agreement by and between Cancer Research Technology Ltd. and the Company, dated as of
October 30, 2003. 
 Exclusive License Agreement on Mitiglinide by and between Kissei Pharmaceutical Co Ltd and the Company as of dated
March 24, 2006 (the “Kissei License Agreement”). 
 Massachusetts Institute of Technology Exclusive Patent License Agreement by
and between the Massachusetts Institute of Technology and the Company, dated as of June 29, 2001. 
 Exclusive License Agreement by and
between the Medical College of Georgia Research Institute, Inc. and the Company, dated as of October 14, 2004. 
 Exclusive License
Agreement by and between Northwestern University and the Company, dated as of June 3, 2005. 
 The Regents of the University of
California Exclusive License Agreement with the Company for “Eukaryotic Genes Involved in Adult Life Span Regulation,” UC Case Nos. SF99-088 and SF03-008, by and between The Regents of the University of California and the Company, dated as
of December 17, 2002, as amended on February 1, 2003. 
 Exclusive License Agreement for Tubulin Acetylation and Mitochondrial
Histone Deacetylase, UC Case Nos. 2004-242, by and between the Regents of the University of California and the Company dated as of December 6, 2004. 
 Exclusive License Agreement for SIRT1 and HIV Transcription, UC Case Nos. 2004-242, by and between the Regents of the University of California and the Company dated as of May 10, 2005.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]